BCC 2021 | Real-world outcomes of HER2+ and TNBC patients recieving neoadjuvant chemotherapy

Bernardo Leon Rapoport, MD, The Medical Oncology Centre of Rosebank, Johannesburg, & Department of Immunology, University of Pretoria, Pretoria, South Africa, discusses the real-world outcomes of HER2+ and triple-negative breast cancer (TNBC) patients who were treated with neoadjuvant chemotherapy. The results of this retrospective analysis demonstrate that TNBC and HER2+ subsets are associated with a higher pathological complete response, with the real-world results being similar to those reported in clinical trial settings. This interview took place during the 17th St. Gallen International Breast Cancer Conference.